Helix BioPharma (TSE: HBP) CEO Dr Heman Chao sat down with Steve Darling from Proactive in New York to share details they have just completed a fundraise. Chao also talked about his desire to uplist the company to the Nasdaq.
Dr Chao also told Proactive what is planned this year in the development of their L-DOS47 cancer drug.
Price: - -
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
CB Therapeutics CEO Sher Butt joined Steve Darling with news the company has recently hit another milestone finding, in early testing, the analysis of raw analytical samples has shown the biosynthetic process of psilocybin, psilocin and related tryptamine-based compounds to be significantly more...
Retail & consumer
Esports betting firm Luckbox to list on the TSX Venture Exchange
Health
Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3...
Mining
